Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...

Novo Nordisk launches NovoCare Pharmacy, offering uninsured and cash-paying patients Wegovy for $499 per month. The service ...

Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMCMark Hope appointed as Senior Vice President, ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

EV shipments in China tumbled in the month of February, plunging 49% year-over-year. Yahoo Finance senior autos reporter Pras ...

"Significant stockholders" now control a vast majority of the struggling company's shares and have left the door open for a ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...